How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia-due-to-klebsiella-pneumoniae.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia due to Klebsiella pneumoniae — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia due to Klebsiella pneumoniae (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Klebsiella pneumoniae, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Avelox	Avelox	Novartis Pharmaceuticals		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A
Amoxycillin	Amoxycillin	King George's Medical University		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Lg Chem Ltd · 2 drugs in Pneumonia due to Klebsiella pneumoniae
Bayer AG · 1 drug in Pneumonia due to Klebsiella pneumoniae
Dr Reddys Labs Inc · 1 drug in Pneumonia due to Klebsiella pneumoniae
Generic (originally Beecham/GSK) · 1 drug in Pneumonia due to Klebsiella pneumoniae
King George's Medical University · 1 drug in Pneumonia due to Klebsiella pneumoniae
Novartis Pharmaceuticals · 1 drug in Pneumonia due to Klebsiella pneumoniae
· 1 drug in Pneumonia due to Klebsiella pneumoniae
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Pneumonia due to Klebsiella pneumoniae

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Klebsiella pneumoniae:

Cite this brief

Drug Landscape (2026). Pneumonia due to Klebsiella pneumoniae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-klebsiella-pneumoniae. Accessed 2026-06-10.

Pneumonia due to Klebsiella pneumoniae full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing